The era of in vivo T cell engineering.
Journal
Med (New York, N.Y.)
ISSN: 2666-6340
Titre abrégé: Med
Pays: United States
ID NLM: 101769215
Informations de publication
Date de publication:
11 02 2022
11 02 2022
Historique:
entrez:
19
5
2022
pubmed:
20
5
2022
medline:
24
5
2022
Statut:
ppublish
Résumé
Cell therapy with genetically engineered T cells has revolutionized the treatment of malignant diseases, but its potential use beyond the realms of oncology has been underexplored. In a recent study, Rurik et al.
Identifiants
pubmed: 35590210
pii: S2666-6340(22)00047-2
doi: 10.1016/j.medj.2022.01.012
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
85-86Commentaires et corrections
Type : CommentOn
Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests G.C.R. has no conflicts to declare. M.H. is listed as an inventor on patent applications and granted patents related to CAR technologies that have been licensed, in part, to industry. M.H. is a co-founder and equity owner of T-CURX GmbH, Würzburg, Germany.